Table 2.

All hormone related clinical trials in this review

First author (year)	Drug	Dose	Study design	Median treatment duration (months)	Number of patients	Sex	Median age (years)	Primary outcome
Markwalder (1985) [47]	Tamoxifen	10 mg orally t.i.d	Prospective cohort; pilot study	12	6‡	5 F; 1 M	71.5	4 assessed; 1 non-specific response; 2 stable; 1 progressed
Goodwin (1993) [48]	Tamoxifen	40 mg b.i.d. for 4 days then 10 mg orally b.i.d	Prospective cohort; phase II	31	21‡	14 F; 7 M	58	1 partial response; 2 minor response; 6 stable; 10 progressed
Grunberg (1990) [50]	Megestrol acetate	40–80 mg orally q.i.d	Prospective cohort	5	9	5 F; 4 M	40	2 stable; 7 progressed
Grunberg (2006) [51]	Mifepristone 14-day course of dexamethasone 1 mg	200 mg q.d. orally	Prospective cohort	35	28	19 F; 9 M	56	5 minor response; 3 clinical without radiographic improvement; 2 progressed
Touat (2014) [52]	Mifepristone	200 mg q.d. orally	Case series	60	3	3 F	54	100% had > 20% volume reduction
Ji (2015) [42]	Mifepristone	200 mg b.i.d. or placebo orally	Randomized phase III clinical trial	Placebo 11[6-18]; mifepristone 10[7–13]+	164	116 F; 48 M	57	HR 1.02 95%CI[0.72, 1.48] Adjusted P = 0.9

^‡Cohort statistics includes patients that were not included in the trial aggregated by publishing author

⁺Failure free survival